M&A Deal Summary |
|
---|---|
Date | 2023-04-25 |
Target | Spectrum Pharmaceuticals |
Sector | Life Science |
Buyer(s) | Assertio |
Deal Type | Add-on Acquisition |
Deal Value | 248M USD |
Advisor(s) | Guggenheim Securities (Financial) Gibson, Dunn & Crutcher (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1995 |
Sector | Life Science |
Employees | 53 |
Revenue | 152M USD (2023) |
Assertio is a pharmaceutical company focused on products to treat pain and other central nervous system (CNS) conditions. Assertio was founded in 1995 and is based in Lake Forest, Illinois.
DEAL STATS | # |
---|---|
Overall | 4 of 4 |
Sector (Life Science) | 3 of 3 |
Type (Add-on Acquisition) | 1 of 1 |
State (Massachusetts) | 1 of 1 |
Country (United States) | 4 of 4 |
Year (2023) | 1 of 1 |
Size (of disclosed) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-12-15 |
Otrexup
New Jersey, United States Otrexup is a drug-device combination single dose once weekly auto-injector containing a prescription medicine, methotrexate, which is indicated for certain adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal anti-inflammatory drugs (NSAIDS) have been used and did not work well. It is also used to control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have been used and did not work well. |
Buy | $44M |